Trial Profile
Influence of a written or oral patient information program in daily clinical practice on adherence and persistence with an aromatase inhibitor in adjuvant primary breast cancer treatment in comparison to standard clinical care within outcome research. - The COMPAS-Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Tamoxifen
- Indications Breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms COMPAS
- Sponsors AstraZeneca
- 04 Sep 2013 COMPAS results published in BMC Cancer.
- 22 Apr 2013 New trial record